Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors

International Immunopharmacology

Volumn 9, Issue 5, 2009, Pages 645-648

  Ozturk, Banu ^a   Coskun, Ugur ^a   Sancak, Banu ^a   Yaman, Emel ^a   Buyukberber, Suleyman ^a   Benekli, Mustafa ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Apoptosis; Head and neck tumor; M30; M65

Indexed keywords

M30 ANTIGEN; M65 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CYTOKERATIN 18; DIAGNOSTIC KIT; PEPTIDE FRAGMENT; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; APOPTOSIS; BLOOD; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; DIAGNOSTIC KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DRUG THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KERATIN-18; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 63549125876     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.02.004     Document Type: Article

References (17)

1. Caulín C., Salvesen G.S., and Oshima R.G. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138 (1997) 1379-1394
2. Ku N.O., Liao J., and Omary M.B. Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272 (1997) 33197-33203
3. MacFarlane M., Merrison W., Dinsdale D., and Cohen G.M. Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. J Cell Biol 148 (2000) 1239-1254
4. Leers M.P., Kölgen W., Björklund V., Bergman T., Tribbick G., Persson B., et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187 (1999) 567-572
5. Galluzzi L., Maiuri M.C., Vitale I., Zischka H., Castedo M., Zitvogel L., et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 14 (2007) 1237-1243
6. Cummings J., Ward T.H., LaCasse E., Lefebvre C., St-Jean M., Durkin J., et al. Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92 (2005) 532-538
7. Kramer G., Schwarz S., Hägg M., Havelka A.M., and Linder S. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 94 (2006) 1592-1598
8. Cummings J., Ranson M., Lacasse E., Ganganagari J.R., St-Jean M., Jayson G., et al. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95 (2006) 42-48
9. Cummings J., Ranson M., Butt F., Moore D., and Dive C. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol 60 (2007) 921-924
10. Ueno T., Toi M., Bivén K., Bando H., Ogawa T., and Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 39 (2003) 769-774
11. Ulukaya E., Yilmaztepe A., Akgoz S., Linder S., and Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 56 (2007) 399-404
12. de Haas E.C., di Pietro A., Simpson K.L., Meijer C., Suurmeijer A.J., Lancashire L.J., et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10 (2008) 1041-1048
13. Schutte B., Henfling M., Kölgen W., Bouman M., Meex S., Leers M.P., et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 297 (2004) 11-26
14. Bivén K., Erdal H., Hägg M., Ueno T., Zhou R., Lynch M., et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 8 (2003) 263-268
15. Demiray M., Ulukaya E.E., Arslan M., Gokgoz S., Saraydaroglu O., Ercan I., et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 24 (2006) 669-676
16. Wu Y.X., Wang J.H., Wang H., and Yang X.Y. Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis. Zhonghua Bing Li Xue Za Zhi 32 (2003) 314-318
17. Greystoke A., Cummings J., Ward T., Simpson K., Renehan A., Butt F., et al. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 19 (2008) 990-995